X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through MOU, Prestige and Vaxine will be building a partnership, initially focused on manufacturing and commercialization of Vaxine’s Covid-19 vaccine, Covax-19® and then as Covid-19 enters an endemic phase development of a next generation Covid19/influenza combo vaccine.
Lead Product(s): Covax-19
Therapeutic Area: Infections and Infectious Diseases Product Name: Spikogen
Highest Development Status: ApprovedProduct Type: Vaccine
Recipient: Prestige BioPharma Pte Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 30, 2022
Details:
SpikoGen features the SARS-CoV-2 spike protein and Vaxine’s own Advax-SM adjuvant. The placebo-controlled SpikoGen trial has coprimary endpoints investigating the occurrence of symptomatic Covid-19 and severe Covid-19, with both endpoints.
Lead Product(s): SARS-CoV-2 Recombinant Spike Protein,Advax-SM
Therapeutic Area: Infections and Infectious Diseases Product Name: SpikoGen
Highest Development Status: Phase IIIProduct Type: Vaccine
Recipient: CinnaGen Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2021
Details:
The collaboration aims at developing a Covid-19 vaccine called, COVAX-19®, which is currently undergoing late stage animal testing and is based on Vaxine’s proprietary Advax™ adjuvant technology combined with a recombinant SARS-CoV-2 spike protein.
Lead Product(s): COVAX-19
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Medytox
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 25, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
